MBS 2320

Drug Profile

MBS 2320

Alternative Names: MBS-2320

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Aberdeen
  • Developer Modern Biosciences
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 30 May 2017 Phase-II clinical trials in Rheumatoid arthritis (Adjunctive treatment) in Georgia (PO), Rheumatoid arthritis (Adjunctive treatment) in Moldova (PO) (NCT03139136)
  • 02 May 2017 Modern Biosciences plans a phase IIa trial for Rheumatoid arthritis (Adjunctive treatment) (NCT03139136)
  • 01 Mar 2017 Modern Biosciences completes a phase I trial in Rheumatoid arthritis (Adjunctive treatment) in United Kingdom (NCT02480946)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top